TriSalus Life Sciences, Inc. (TLSI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$5.00+0.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
TriSalus aims to grow revenue to about $55 million in 2026. It is working to get FDA clearance for TriNav Advance. The company is improving its leadership team and beat earnings recently. These steps could lead to better cancer treatments and future growth.
TriSalus is still losing money with operating income down to -$8.41 million in 2026-Q1. Revenue guidance was lowered despite expansion efforts. The company faces high risk and uncertain progress on FDA clearance.
The price is about 0% above our fair value near $4. Analysts expect 46% revenue growth. Our view is cautious given the company’s losses and mixed progress on key goals.
Breaks if: FDA clearance not achieved by end of 2026
Breaks if: Operating loss worsens beyond -$8.41 million over next 4 quarters
Revenue falls below $54 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround situation. TLSI is currently loss-making and has mixed management execution, but it is focused on expanding its commercial operations and achieving FDA clearance for a key device.
The market appears to have a low expectations gap, suggesting that it has priced in some level of fragility. TLSI is valued at a premium compared to its peers, indicating that investors may expect improvement in its fundamentals.
Management has shown some progress in revenue growth, but overall financial performance remains weak. Operating losses have increased despite improved gross margins, which indicates challenges in cost management.
The long-term thesis hinges on the company's ability to maintain revenue growth, achieve FDA clearance for its device, and navigate potential economic downturns. The performance of larger healthcare companies could also influence TLSI's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, TLSI's outlook depends on its execution of growth strategies and external market conditions. Not investment advice.